
David M Maahs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4599060/publications.pdf Version: 2024-02-01



ΠΛΛΙΟ Μ ΜΛΛΗς

#	Article	IF	CITATIONS
1	More hypoglycemia not associated with increasing estimated adiposity in youth with type 1 diabetes. Pediatric Research, 2023, 93, 708-714.	1.1	2
2	Closing Disparities in Pediatric Diabetes Telehealth Care: Lessons From Telehealth Necessity During the COVID-19 Pandemic. Clinical Diabetes, 2022, 40, 153-157.	1.2	5
3	Changes in HbA1c Between 2011 and 2017 in Germany/Austria, Sweden, and the United States: A Lifespan Perspective. Diabetes Technology and Therapeutics, 2022, 24, 32-41.	2.4	14
4	Age and Hospitalization Risk in People With Type 1 Diabetes and COVID-19: Data From the T1D Exchange Surveillance Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 410-418.	1.8	28
5	Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Type 1 Diabetes: the Pilot 4T Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 998-1008.	1.8	34
6	Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study. Diabetes Technology and Therapeutics, 2022, 24, 157-166.	2.4	7
7	Automation of a multiplex agglutination-PCR (ADAP) type 1 diabetes (T1D) assay for the rapid analysis of islet autoantibodies. SLAS Technology, 2022, 27, 26-31.	1.0	5
8	Trends in Glycemic Control Among Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study. Diabetes Care, 2022, 45, 285-294.	4.3	24
9	Algorithm-Enabled, Personalized Clucose Management for Type 1 Diabetes at the Population Scale: Prospective Evaluation in Clinical Practice. JMIR Diabetes, 2022, 7, e27284.	0.9	10
10	Overcoming Barriers to Diabetes Technology in Youth with Type 1 Diabetes and Public Insurance: Cases and Call to Action. Case Reports in Endocrinology, 2022, 2022, 1-5.	0.2	3
11	Response to Letter to the Editor from Justin M. Gregory: "Age and Hospitalization Risk in People With Type 1 Diabetes and COVID-19: Data From the T1D Exchange Surveillance Study― Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1769-e1770.	1.8	2
12	A New Technology-Enabled Care Model for Pediatric Type 1 Diabetes. NEJM Catalyst, 2022, 3, .	0.4	5
13	Design of the Advancing Care for Type 1 Diabetes and Obesity Network energy metabolism and sequential multiple assignment randomized trial nutrition pilot studies: An integrated approach to develop weight management solutions for individuals with type 1 diabetes. Contemporary Clinical Trials, 2022, 117, 106765.	0.8	9
14	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2022, 24, S-107-S-128.	2.4	2
15	A collaborative comparison of international pediatric diabetes registries. Pediatric Diabetes, 2022, 23, 627-640.	1.2	7
16	Psychosocial Needs for Newly Diagnosed Youth with Type 1 Diabetes and Their Families. Current Diabetes Reports, 2022, 22, 385-392.	1.7	2
17	Associations of Diet With the Intestinal Microbiota and Short-Chain Fatty Acids Among Young Adults With Type 1 Diabetes: The ACT1ON Ancillary Gut Microbiome Pilot Study. Current Developments in Nutrition, 2022, 6, 1012.	0.1	0
18	Advancements and future directions in the teamwork, targets, technology, and tight control—the 4T study: improving clinical outcomes in newly diagnosed pediatric type 1 diabetes. Current Opinion in Pediatrics, 2022, 34, 423-429.	1.0	10

#	Article	IF	CITATIONS
19	50 Years Ago in T J P. Journal of Pediatrics, 2021, 230, 70.	0.9	2
20	Children and youth with diabetes are not at increased risk for hospitalization due to <scp>COVID</scp> â€19. Pediatric Diabetes, 2021, 22, 202-206.	1.2	52
21	50 Years Ago in T J P. Journal of Pediatrics, 2021, 231, 199.	0.9	0
22	A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison. Diabetes Care, 2021, 44, 133-140.	4.3	162
23	Provider Implicit Bias Impacts Pediatric Type 1 Diabetes Technology Recommendations in the United States: Findings from The Gatekeeper Study. Journal of Diabetes Science and Technology, 2021, 15, 1027-1033.	1.3	54
24	â€~I was ready for it at the beginning': Parent experiences with early introduction of continuous glucose monitoring following their child's Type 1 diabetes diagnosis. Diabetic Medicine, 2021, 38, e14567.	1.2	20
25	Full closed loop openâ€source algorithm performance comparison in pigs with diabetes. Clinical and Translational Medicine, 2021, 11, e387.	1.7	11
26	Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes Care, 2021, 44, 1480-1490.	4.3	56
27	Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526–532. Diabet Care, 2021, 44, e102-e102.	es4.3	5
28	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2021, 23, S-113-S-130.	2.4	0
29	50 Years Ago in T J P. Journal of Pediatrics, 2021, 233, 131.	0.9	0
30	Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry. Diabetes Care, 2021, 44, e160-e162.	4.3	20
31	ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2021, 23, 818-827.	2.4	7
32	Democratizing type 1 diabetes specialty care in the primary care setting to reduce health disparities: project extension for community healthcare outcomes (ECHO) T1D. BMJ Open Diabetes Research and Care, 2021, 9, e002262.	1.2	20
33	Engineering Insulin Cold Chain Resilience to Improve Global Access. Biomacromolecules, 2021, 22, 3386-3395.	2.6	12
34	Clinically Serious Hypoglycemia Is Rare and Not Associated With Time-in-range in Youth With New-onset Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3239-3247.	1.8	13
35	Multi-Clinic Quality Improvement Initiative Increases Continuous Clucose Monitoring Use Among Adolescents and Young Adults With Type 1 Diabetes. Clinical Diabetes, 2021, 39, 264-271.	1.2	30
36	Hemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents. Pediatrics, 2021, 148, .	1.0	8

#	Article	IF	CITATIONS
37	Improved individual and population-level HbA1c estimation using CGM data and patient characteristics. Journal of Diabetes and Its Complications, 2021, 35, 107950.	1.2	6
38	50 Years Ago in T J P. Journal of Pediatrics, 2021, 235, 82.	0.9	0
39	Disparities in Hemoglobin A1c Testing During the Transition to Adulthood and Association With Diabetes Outcomes in Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study. Diabetes Care, 2021, 44, 2320-2328.	4.3	2
40	Ultraâ€Fast Insulin–Pramlintide Coâ€Formulation for Improved Glucose Management in Diabetic Rats. Advanced Science, 2021, 8, e2101575.	5.6	10
41	Populationâ€level management of type 1 diabetes via continuous glucose monitoring and algorithmâ€enabled patient prioritization: Precision health meets population health. Pediatric Diabetes, 2021, 22, 982-991.	1.2	18
42	Help when you need it: Perspectives of adults with T1D on the support and training they would have wanted when starting CGM. Diabetes Research and Clinical Practice, 2021, 180, 109048.	1.1	7
43	The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence. Diabetes Care, 2021, 44, 301-312.	4.3	32
44	Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. Diabetes Therapy, 2021, 12, 3093-3105.	1.2	3
45	Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users. Journal of Health Psychology, 2020, 25, 429-438.	1.3	40
46	Estimating Dynamic Treatment Regimes in Mobile Health Using V-Learning. Journal of the American Statistical Association, 2020, 115, 692-706.	1.8	56
47	Understanding adolescent and parent acceptability and feasibility experience in a large Type 1 diabetes mellitus behavioural trial. Diabetic Medicine, 2020, 37, 1134-1145.	1.2	0
48	The Transatlantic HbA _{1c} gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabetic Medicine, 2020, 37, 848-855.	1.2	78
49	HbA1c Levels in Type 1 Diabetes from Early Childhood to Older Adults: A Deeper Dive into the Influence of Technology and Socioeconomic Status on HbA1c in the T1D Exchange Clinic Registry Findings. Diabetes Technology and Therapeutics, 2020, 22, 645-650.	2.4	98
50	Dietary intake on days with and without hypoglycemia in youth with type 1 diabetes: The Flexible Lifestyle Empowering Change trial. Pediatric Diabetes, 2020, 21, 1475-1484.	1.2	4
51	50 Years Ago in T J P. Journal of Pediatrics, 2020, 223, 19.	0.9	0
52	50 Years Ago in T J P. Journal of Pediatrics, 2020, 223, 99.	0.9	0
53	Tele-rounds and Case-Based Training. Pediatric Clinics of North America, 2020, 67, 759-772.	0.9	20
54	50 Years Ago in T J P. Journal of Pediatrics, 2020, 221, 200.	0.9	0

#	Article	IF	CITATIONS
55	The Neighborhood Deprivation Index and Provider Geocoding Identify Critical Catchment Areas for Diabetes Outreach. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3069-3075.	1.8	22
56	Uninterrupted continuous glucose monitoring access is associated with a decrease in <scp>HbA1c</scp> in youth with type 1 diabetes and public insurance. Pediatric Diabetes, 2020, 21, 1301-1309.	1.2	43
57	Improving Clinical Outcomes in Newly Diagnosed Pediatric Type 1 Diabetes: Teamwork, Targets, Technology, and Tight Control—The 4T Study. Frontiers in Endocrinology, 2020, 11, 360.	1.5	39
58	Characterization of youth goal setting in the <scp>selfâ€management</scp> of type 1 diabetes and associations with <scp>HbA1c:</scp> The Flexible Lifestyle Empowering Change trial. Pediatric Diabetes, 2020, 21, 1343-1352.	1.2	8
59	Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes. Pediatric Diabetes, 2020, 21, 1126-1131.	1.2	5
60	COVID-19 and Children With Diabetes—Updates, Unknowns, and Next Steps: First, Do No Extrapolation. Diabetes Care, 2020, 43, 2631-2634.	4.3	60
61	Weight Management in Youth with Type 1 Diabetes and Obesity: Challenges and Possible Solutions. Current Obesity Reports, 2020, 9, 412-423.	3.5	13
62	CGM Initiation Soon After Type 1 Diabetes Diagnosis Results in Sustained CGM Use and Wear Time. Diabetes Care, 2020, 43, e3-e4.	4.3	39
63	A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs. Nature Biomedical Engineering, 2020, 4, 507-517.	11.6	52
64	Enhancing resources for healthcare professionals caring for people on intensive insulin therapy: Summary from a national workshop. Diabetes Research and Clinical Practice, 2020, 164, 108169.	1.1	5
65	Unintended Consequences of Coronavirus Disease-2019: Remember General Pediatrics. Journal of Pediatrics, 2020, 223, 197-198.	0.9	70
66	Glucose Control During Physical Activity and Exercise Using Closed Loop Technology in Adults and Adolescents with Type 1 Diabetes. Canadian Journal of Diabetes, 2020, 44, 740-749.	0.4	46
67	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2020, 22, S-89-S-108.	2.4	0
68	50 Years Ago in T J P. Journal of Pediatrics, 2020, 217, 78.	0.9	0
69	International benchmarking in type 1 diabetes: Large difference in childhood <scp>HbA1c</scp> between eight highâ€income countries but similar rise during adolescence—A quality registry study. Pediatric Diabetes, 2020, 21, 621-627.	1.2	43
70	Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (<scp>United States</scp>) and the prospective diabetes followâ€up (Germany/Austria) registries. Diabetes, Obesity and Metabolism, 2020, 22, 1577-1585.	2.2	39
71	Primary Care Providers in California and Florida Report Low Confidence in Providing Type 1 Diabetes Care. Clinical Diabetes, 2020, 38, 159-165.	1.2	18
72	Multimethod, multidataset analysis reveals paradoxical relationships between sociodemographic factors, Hispanic ethnicity and diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001725.	1.2	1

#	Article	IF	CITATIONS
73	Dysglycemia among youth with type 1 diabetes and suboptimal glycemic control in The Flexible Lifestyle Empowering Change (FLEX) trial. Pediatric Diabetes, 2019, 20, 180-188.	1.2	3
74	Five heterogeneous HbA1c trajectories from childhood to adulthood in youth with type 1 diabetes from three different continents: A groupâ€based modeling approach. Pediatric Diabetes, 2019, 20, 920-931.	1.2	37
75	Elevated copeptin, arterial stiffness, and elevated albumin excretion in adolescents with type 1 diabetes. Pediatric Diabetes, 2019, 20, 1110-1117.	1.2	10
76	Optimizing Basal Insulin Dosing. Journal of Pediatrics, 2019, 215, 7-8.	0.9	2
77	Hemoglobin A1c Trajectory in Pediatric Patients with Newly Diagnosed Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 456-461.	2.4	26
78	Serum uromodulin is associated with urinary albumin excretion in adolescents with type 1 diabetes. Journal of Diabetes and Its Complications, 2019, 33, 648-650.	1.2	10
79	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. Journal of the American Society of Nephrology: JASN, 2019, 30, 2000-2016.	3.0	135
80	50 Years Ago in T J P. Journal of Pediatrics, 2019, 214, 70.	0.9	0
81	Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in aÂyoung adult population. Journal of Clinical Lipidology, 2019, 13, 940-946.	0.6	15
82	One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System. Diabetes Care, 2019, 42, 2190-2196.	4.3	168
83	Genetic Determinants of Clycated Hemoglobin in Type 1 Diabetes. Diabetes, 2019, 68, 858-867.	0.3	14
84	State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology and Therapeutics, 2019, 21, 66-72.	2.4	1,332
85	Models, Devices, Properties, and Verification of Artificial Pancreas Systems. Computational Biology, 2019, , 93-131.	0.1	6
86	Assessment of a Precision Medicine Analysis of a Behavioral Counseling Strategy to Improve Adherence to Diabetes Self-management Among Youth. JAMA Network Open, 2019, 2, e195137.	2.8	1
87	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	4.3	39
88	Using patient reported outcomes in diabetes research and practice: Recommendations from a national workshop. Diabetes Research and Clinical Practice, 2019, 153, 23-29.	1.1	25
89	Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. Pediatric Diabetes, 2019, 20, 556-566.	1.2	8
90	Closed loop control in adolescents and children during winter sports: Use of the Tandem Controlâ€IQ AP system. Pediatric Diabetes, 2019, 20, 759-768.	1.2	47

#	Article	IF	CITATIONS
91	Artificial pancreas in pediatrics. , 2019, , 237-259.		1
92	Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial. Diabetes Technology and Therapeutics, 2019, 21, 159-169.	2.4	76
93	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2019, 21, S-123-S-137.	2.4	5
94	Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?. Lancet Diabetes and Endocrinology,the, 2018, 6, 809-820.	5.5	51
95	Measured GFR in Routine Clinical Practice—The Promise of Dried Blood Spots. Advances in Chronic Kidney Disease, 2018, 25, 76-83.	0.6	35
96	Role of bicarbonate supplementation on urine uric acid crystals and diabetic tubulopathy in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1776-1780.	2.2	13
97	Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting. Diabetes Technology and Therapeutics, 2018, 20, 335-343.	2.4	64
98	Exploring Variation in Glycemic Control Across and Within Eight High-Income Countries: A Cross-sectional Analysis of 64,666 Children and Adolescents With Type 1 Diabetes. Diabetes Care, 2018, 41, 1180-1187.	4.3	81
99	Sex-specific differences in insulin resistance in type 1 diabetes: The CACTI cohort. Journal of Diabetes and Its Complications, 2018, 32, 418-423.	1.2	19
100	Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas. Journal of Diabetes Science and Technology, 2018, 12, 599-607.	1.3	21
101	Meta-genome-wide association studies identify a locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1 diabetes. Diabetologia, 2018, 61, 1098-1111.	2.9	26
102	Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care, 2018, 41, 789-796.	4.3	101
103	Quantifying genetic susceptibility in T1DM — implications for diagnosis after age 30. Nature Reviews Endocrinology, 2018, 14, 134-135.	4.3	1
104	Diabetes technology: improving care, improving patientâ€reported outcomes and preventing complications in young people with Type 1 diabetes. Diabetic Medicine, 2018, 35, 419-429.	1.2	84
105	The Flexible Lifestyle Empowering Change (FLEX) intervention for self-management in adolescents with type 1 diabetes: Trial design and baseline characteristics. Contemporary Clinical Trials, 2018, 66, 64-73.	0.8	18
106	Guidelines to Practice: Identifying Barriers to Cardiovascular Health Management in Pediatric Type 1 Diabetes. Journal of Pediatrics, 2018, 197, 14-15.	0.9	2
107	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2018, 20, S-114-S-127.	2.4	0
108	Predictive hyperglycemia and hypoglycemia minimization: Inâ€home doubleâ€blind randomized controlled evaluation in children and young adolescents. Pediatric Diabetes, 2018, 19, 420-428.	1.2	19

#	Article	IF	CITATIONS
109	Dynamic changes in retinal vessel diameter during acute hyperglycemia in type 1 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 234-239.	1.2	7
110	The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration. Pediatric Diabetes, 2018, 19, 14-17.	1.2	23
111	The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 1160-1168.	1.2	25
112	ISPAD Clinical Practice Consensus Guidelines 2018: What is new in diabetes care?. Pediatric Diabetes, 2018, 19, 5-6.	1.2	20
113	ISPAD Clinical Practice Consensus Guidelines 2018: Limited Care Guidance Appendix. Pediatric Diabetes, 2018, 19, 328-338.	1.2	11
114	Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocrine Reviews, 2018, 39, 629-663.	8.9	154
115	Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. Diabetes Technology and Therapeutics, 2018, 20, 648-653.	2.4	29
116	Two-step recruitment process optimizes retention in FLEX clinical trial. Contemporary Clinical Trials Communications, 2018, 12, 68-75.	0.5	5
117	A Data-Driven Approach to Artificial Pancreas Verification and Synthesis. , 2018, , .		9
118	ISPAD Clinical Practice Consensus Guidelines 2018: Introduction to the Limited Care guidance appendix. Pediatric Diabetes, 2018, 19, 326-327.	1.2	5
119	Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. Pediatric Diabetes, 2018, 19, 1271-1275.	1.2	186
120	Eating patterns and food intake of persons with type 1 diabetes within the T1D exchange. Diabetes Research and Clinical Practice, 2018, 141, 217-228.	1.1	27
121	ISPAD Annual Conference 2017 Highlights. Pediatric Diabetes, 2018, 19, 855-858.	1.2	0
122	ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatric Diabetes, 2018, 19, 105-114.	1.2	464
123	Efficacy of the Flexible Lifestyles Empowering Change intervention on metabolic and psychosocial outcomes in adolescents with type 1 diabetes (FLEX): a randomised controlled trial. The Lancet Child and Adolescent Health, 2018, 2, 635-646.	2.7	40
124	Sustained Continuous Glucose Monitor Use in Low-Income Youth with Type 1 Diabetes Following Insurance Coverage Supports Expansion of Continuous Glucose Monitor Coverage for All. Diabetes Technology and Therapeutics, 2018, 20, 632-634.	2.4	32
125	ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies. Pediatric Diabetes, 2018, 19, 302-325.	1.2	170
126	Can Real World Evidence on Body Mass Index Trajectories Inform Clinical Practice?. Journal of Pediatrics, 2018, 201, 10-11.	0.9	0

#	Article	IF	CITATIONS
127	Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D Exchange. Diabetes Technology and Therapeutics, 2018, 20, 517-523.	2.4	27
128	ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. Pediatric Diabetes, 2018, 19, 28-46.	1.2	180
129	Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care, 2018, 41, 2026-2044.	4.3	288
130	ISPAD Clinical Practice Consensus Guidelines 2018: The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatric Diabetes, 2018, 19, 84-104.	1.2	81
131	Age at type 1 diabetes onset: a new risk factor and call for focused treatment. Lancet, The, 2018, 392, 453-454.	6.3	11
132	ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes, 2018, 19, 178-192.	1.2	172
133	Advances in Care for Insulin-Requiring Patients Without Closed Loop. Diabetes Technology and Therapeutics, 2018, 20, S2-85-S2-91.	2.4	8
134	Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes. Diabetes Care, 2017, 40, 359-366.	4.3	20
135	Predictors of Dyslipidemia Over Time in Youth With Type 1 Diabetes: For the SEARCH for Diabetes in Youth Study. Diabetes Care, 2017, 40, 607-613.	4.3	35
136	In-Home Closed Loop Control for Artificial Pancreas: Patient and Provider Perspective. Diabetes Technology and Therapeutics, 2017, 19, 4-6.	2.4	6
137	Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Pediatric Diabetes, 2017, 18, 755-760.	1.2	38
138	Response to Comment on Hofer et al. International Comparison of Smoking and Metabolic Control in Patients With Type 1 Diabetes. Diabetes Care 2016;39:e177–e178. Diabetes Care, 2017, 40, e37-e37.	4.3	0
139	Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers. Vascular Medicine, 2017, 22, 85-95.	0.8	49
140	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2017, 19, S-105-S-119.	2.4	1
141	Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. Diabetes Technology and Therapeutics, 2017, 19, 331-339.	2.4	56
142	Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1340-1347.	1.2	15
143	Behavioural implications of traditional treatment and closedâ€loop automated insulin delivery systems in Type 1 diabetes: applying a cognitive restraint theory framework. Diabetic Medicine, 2017, 34, 1500-1507.	1.2	12
144	Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. Diabetes Care, 2017, 40, 1096-1102.	4.3	46

#	Article	IF	CITATIONS
145	Clinical Use of Continuous Glucose Monitoring in Pediatrics. Diabetes Technology and Therapeutics, 2017, 19, S-37-S-43.	2.4	20
146	Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. Diabetes Care, 2017, 40, 1034-1040.	4.3	104
147	PCSK9 Is Increased in Youth With Type 1 Diabetes. Diabetes Care, 2017, 40, e85-e87.	4.3	20
148	Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Diabetes Educator, 2017, 43, 223-232.	2.6	78
149	Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: A brief report from the T1D exchange Biobank. Journal of Diabetes and Its Complications, 2017, 31, 387-389.	1.2	13
150	Response to Comment on Craig et al. Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. Diabetes Care 2017;40:1034–1040. Diabetes Care, 2017, 40, e168-e169.	4.3	3
151	Implementation of Depression Screening and Clobal Health Assessment in Pediatric Subspecialty Clinics. Journal of Adolescent Health, 2017, 61, 591-598.	1.2	44
152	Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. Diabetes Care, 2017, 40, 1644-1650.	4.3	130
153	Predictors of early renal function decline in adults with TypeÂ1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes and the Pittsburgh Epidemiology of Diabetes Complications studies. Diabetic Medicine, 2017, 34, 1532-1540.	1.2	11
154	Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries. Diabetes Care, 2017, 40, e139-e140.	4.3	44
155	Closed-Loop Control Without Meal Announcement in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 527-532.	2.4	87
156	International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 2017, 40, 1631-1640.	4.3	1,376
157	Biopsychosocial Aspects of Weight Management in Type 1 Diabetes: a Review and Next Steps. Current Diabetes Reports, 2017, 17, 58.	1.7	46
158	A survey of youth with new onset type 1 diabetes: Opportunities to reduce diabetic ketoacidosis. Pediatric Diabetes, 2017, 18, 547-552.	1.2	22
159	Adiponectin is associated with early diabetic kidney disease in adults with type 1 diabetes: A Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Journal of Diabetes and Its Complications, 2017, 31, 369-374.	1.2	19
160	Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension. Pediatric Diabetes, 2017, 18, 422-427.	1.2	10
161	Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatric Diabetes, 2017, 18, 643-650.	1.2	74
162	Continuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs). Sensors, 2017, 17, 161.	2.1	21

#	Article	IF	CITATIONS
163	Prediction of acute coronary syndromes by urinary proteome analysis. PLoS ONE, 2017, 12, e0172036.	1.1	30
164	Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care, 2016, 39, 1175-1179.	4.3	195
165	Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes. Pediatric Diabetes, 2016, 17, 257-265.	1.2	22
166	The Comez equations and renal hemodynamic function in kidney disease research. American Journal of Physiology - Renal Physiology, 2016, 311, F967-F975.	1.3	35
167	Effects of Frequency of Sensor-Augmented Pump Use on HbA1cand C-Peptide Levels in the First Year of Type 1 Diabetes. Diabetes Care, 2016, 39, e61-e62.	4.3	5
168	Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 1216-1221.	1.3	31
169	Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1093-1096.	1.2	34
170	Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. Diabetes Research and Clinical Practice, 2016, 122, 28-37.	1.1	41
171	Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry. Pediatric Diabetes, 2016, 17, 15-20.	1.2	32
172	Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 1268-1276.	1.3	37
173	Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry. Pediatric Diabetes, 2016, 17, 38-45.	1.2	108
174	Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 429-435.	2.4	27
175	Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies. Current Diabetes Reports, 2016, 16, 11.	1.7	28
176	Development and Validation of a Method to Estimate Insulin Sensitivity in Patients With and Without Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 686-695.	1.8	44
177	Estimated insulin sensitivity predicts incident micro- and macrovascular complications in adults with type 1 diabetes over 6 years: the coronary artery calcification in type 1 diabetes study. Journal of Diabetes and Its Complications, 2016, 30, 586-590.	1.2	47
178	Reduced brachial artery distensibility in patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 893-897.	1.2	6
179	Hyperfiltration and uricosuria in adolescents with type 1 diabetes. Pediatric Nephrology, 2016, 31, 787-793.	0.9	23
180	Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia, 2016, 59, 87-91.	2.9	203

#	Article	IF	CITATIONS
181	Periodontal Microorganisms and Cardiovascular Risk Markers in Youth With Type 1 Diabetes and Without Diabetes. Journal of Periodontology, 2016, 87, 376-384.	1.7	5
182	Prevalence of cardiovascular risk factors in youth with type 1 diabetes and elevated body mass index. Acta Diabetologica, 2016, 53, 271-277.	1.2	55
183	Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting. Acta Diabetologica, 2016, 53, 331-333.	1.2	8
184	Flexible Lifestyles for Youth (<scp>FL</scp> 3X) behavioural intervention for atâ€risk adolescents with Type 1 diabetes: a randomized pilot and feasibility trial. Diabetic Medicine, 2015, 32, 829-833.	1.2	10
185	Factors Associated with Nocturnal Hypoglycemia in At-Risk Adolescents and Young Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2015, 17, 385-391.	2.4	43
186	Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. Diabetes Care, 2015, 38, 971-978.	4.3	1,082
187	Renal Function Is Associated With Peak Exercise Capacity in Adolescents With Type 1 Diabetes. Diabetes Care, 2015, 38, 126-131.	4.3	22
188	Elevated risk of mortality in type 1 diabetes mellitus. Nature Reviews Endocrinology, 2015, 11, 136-138.	4.3	10
189	Relation of Combined Non–High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis inÂAdults With Type 1 Diabetes Mellitus. American Journal of Cardiology, 2015, 116, 1057-1062.	0.7	16
190	Diabetes Complications in Childhood Diabetes: New Biomarkers and Technologies. Current Pediatrics Reports, 2015, 3, 177-186.	1.7	13
191	Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrology Dialysis Transplantation, 2015, 30, 1706-1711.	0.4	88
192	Effect of Lipohypertrophy on Accuracy of Continuous Glucose Monitoring in Patients With Type 1 Diabetes. Diabetes Care, 2015, 38, e166-e167.	4.3	17
193	Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis. Diabetes Care, 2015, 38, 1197-1204.	4.3	129
194	Rates of Diabetic Ketoacidosis: International Comparison With 49,859 Pediatric Patients With Type 1 Diabetes From England, Wales, the U.S., Austria, and Germany. Diabetes Care, 2015, 38, 1876-1882.	4.3	178
195	Adiponectin-SOGA Dissociation in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1065-E1073.	1.8	7
196	Insulin sensitivity and complications in type 1 diabetes: New insights. World Journal of Diabetes, 2015, 6, 8.	1.3	43
197	Insulin Sensitivity Is an Important Determinant of Renal Health in Adolescents With Type 2 Diabetes. Diabetes Care, 2014, 37, 3033-3039.	4.3	41
198	Frequency of Morning Ketosis After Overnight Insulin Suspension Using an Automated Nocturnal Predictive Low Glucose Suspend System. Diabetes Care, 2014, 37, 1224-1229.	4.3	42

#	Article	IF	CITATIONS
199	Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus. Circulation, 2014, 130, 1532-1558.	1.6	150
200	Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: The Coronary Artery Calcification in Type 1 Diabetes Study. Journal of Clinical Lipidology, 2014, 8, 576-583.	0.6	31
201	Assessment and monitoring of glycemic control in children and adolescents withÂdiabetes. Pediatric Diabetes, 2014, 15, 102-114.	1.2	274
202	The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatric Diabetes, 2014, 15, 86-101.	1.2	46
203	A Novel Method to Detect Pressure-Induced Sensor Attenuations (PISA) in an Artificial Pancreas. Journal of Diabetes Science and Technology, 2014, 8, 1091-1096.	1.3	64
204	The Effects of Lowering Nighttime and Breakfast Glucose Levels with Sensor-Augmented Pump Therapy on Hemoglobin A1c Levels in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2014, 16, 284-291.	2.4	17
205	Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes. Journal of Diabetes and Its Complications, 2014, 28, 298-304.	1.2	30
206	ABC goal achievement predicts microvascular but not macrovascular complications over 6-years in adults with type 1 diabetes: The Coronary Artery Calcification in Type 1 Diabetes Study. Journal of Diabetes and Its Complications, 2014, 28, 762-766.	1.2	13
207	A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes. Diabetes Care, 2014, 37, 1885-1891.	4.3	141
208	Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry. Diabetes Care, 2014, 37, 2702-2709.	4.3	278
209	The effect of insurance status and parental education on glycemic control and cardiovascular disease risk profile in youth with Type 1 Diabetes. Journal of Diabetes and Metabolic Disorders, 2014, 13, 59.	0.8	14
210	Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6Âyears of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia, 2014, 57, 1578-1585.	2.9	147
211	A practical method to measure GFR in people with type 1 diabetes. Journal of Diabetes and Its Complications, 2014, 28, 667-673.	1.2	21
212	Frequency of Continuous Glucose Monitoring use and Change in Hemoglobin A1C for Adults With Type 1 Diabetes in a Clinical Practice Setting. Endocrine Practice, 2014, 20, 1007-1015.	1.1	12
213	Fasting Blood Glucose-A Missing Variable for GFR-Estimation in Type 1 Diabetes?. PLoS ONE, 2014, 9, e96264.	1.1	11
214	Outpatient Safety Assessment of an In-Home Predictive Low-Glucose Suspend System with Type 1 Diabetes Subjects at Elevated Risk of Nocturnal Hypoglycemia. Diabetes Technology and Therapeutics, 2013, 15, 622-627.	2.4	89
215	The Importance of Palmitoleic Acid to Adipocyte Insulin Resistance and Whole-Body Insulin Sensitivity in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E40-E50.	1.8	38
216	Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3411-3419.	1.8	258

#	Article	IF	CITATIONS
217	Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. Diabetes Care, 2013, 36, 2035-2037.	4.3	360
218	Lower A1c among adolescents with lower perceived A1c goal: a cross-sectional survey. International Journal of Pediatric Endocrinology (Springer), 2013, 2013, 17.	1.6	18
219	Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1663-1672.	1.8	76
220	Current Knowledge and Future Directions on Cardiovascular Disease in Diabetes. Diabetes Technology and Therapeutics, 2012, 14, S-75-S-76.	2.4	1
221	Sugar-sweetened and diet beverage consumption is associated with cardiovascular risk factor profile in youth with type 1 diabetes. Acta Diabetologica, 2011, 48, 275-282.	1.2	49
222	Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes. Diabetes, 2011, 60, 306-314.	0.3	182
223	Epidemiology of Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 2010, 39, 481-497.	1.2	829
224	Weight and elevated albumin to creatinine ratio in youth with diabetes: the SEARCH for Diabetes in Youth study. Pediatric Nephrology, 2008, 23, 2255-2260.	0.9	7
225	Dyslipidemia in Youth with Diabetes: To Treat or Not to Treat?. Journal of Pediatrics, 2008, 153, 458-465.e4.	0.9	44
226	Determinants of Serum Adiponectin in Persons with and without Type 1 Diabetes. American Journal of Epidemiology, 2007, 166, 731-740.	1.6	37
227	Serum Cystatin C Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals With Type 1 Diabetes. Diabetes, 2007, 56, 2774-2779.	0.3	69
228	Higher Prevalence of Elevated Albumin Excretion in Youth With Type 2 Than Type 1 Diabetes: The SEARCH for Diabetes in Youth Study. Diabetes Care, 2007, 30, 2593-2598.	4.3	138
229	ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. Journal of Diabetes and Its Complications, 2007, 21, 273-279.	1.2	21
230	Longitudinal Lipid Screening and Use of Lipid-Lowering Medications in Pediatric Type 1 Diabetes. Journal of Pediatrics, 2007, 150, 146-150.e2.	0.9	62
231	Randomized, Double-Blind, Placebo-Controlled Trial of Orlistat for Weight Loss in Adolescents. Endocrine Practice, 2006, 12, 18-28.	1.1	137
232	Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification. Circulation, 2005, 111, 747-753.	1.6	268
233	Hypertension Prevalence, Awareness, Treatment, and Control in an Adult Type 1 Diabetes Population and a Comparable General Population. Diabetes Care, 2005, 28, 301-306.	4.3	125
234	Total Cholesterol and High-Density Lipoprotein Levels in Pediatric Subjects with Type 1 Diabetes Mellitus. Journal of Pediatrics, 2005, 147, 544-546.	0.9	45